Hopefully, but a similar technology applied to influenza to cover all variants has never been marketed. It’s a long way from promising early results to mass production and delivery of a vaccine. That’s one of the remarkable aspects of the mRNA vaccines. It also shows what can be done when the government invests billions to facilitate development, ramp up manufacturing capacity, and accelerate production and distribution with zero risk to the developer. Normally, such projects are killed by management because of a litany of uncertainties that they characterize as risks.